Multi-kinase-IN-14 

Multi-kinase-IN-14 is an orally active and blood-brain barrier-permeable multi-kinase inhibitor. Multi-kinase-IN-14 reduces the excessive phosphorylation of α-synuclein by inhibiting four kinases (ABL1, DYRK1A, GSK3β, and LRRK2) and stabilizing microtubules. Multi-kinase-IN-14 is applicable for research on neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease^[1].

Multi-kinase-IN-14 (10 μM) exhibits mild inhibition of ABL1, DYRK1A, GSK3β, and LRRK2 kinase activities in an in vitro kinase assay, with average inhibition rates of 56.5%, 48%, 61%, and 59%, respectively^[1].
Multi-kinase-IN-14 (100 μM) inhibits the binding of colchicine (HY-16569) to tubulin with a 34% inhibition rate^[1].
Multi-kinase-IN-14 (50 μM) inhibits the binding of vinblastine (HY-13780) to tubulin with a 15% inhibition rate^[1].
Multi-kinase-IN-14 (4-8 μM; 10 days) reduces α-synuclein fibril-induced excessive phosphorylation at Ser129, nuclear fragmentation and condensation, and moderately increases acetylated α-tubulin levels in primary rat hippocampal cell cultures^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Multi-kinase-IN-14 (5 mg/kg, p.o.) moderately reduces the excessive phosphorylation of insoluble α-synuclein in the central nervous system of mice pre-injected with pre-formed fibrils^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

323.78

C₁₇H₁₄ClN₅

2201083-51-2

NC1=NC2=C(C(N(C3=CC=CC=C3)C)=N1)C4=C(C=CC=C4Cl)N2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Vyas J, et al. Discovery of multitargeting single agents as a novel route to the potential treatment of neurodegenerative diseases. Bioorg Med Chem Lett. 2026;133:130536.  [Content Brief]